

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2008 (24.04.2008)

PCT

(10) International Publication Number
WO 2008/047242 A8

(51) International Patent Classification:
C07K 16/28 (2006.01) C07K 16/46 (2006.01)

(21) International Application Number:
PCT/IB2007/004172

(22) International Filing Date: 16 October 2007 (16.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06 291 628.3 19 October 2006 (19.10.2006) EP

(71) Applicant (for all designated States except US): **SANOFI-AVENTIS** [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PARK, Peter U.** [US/US]; 128 Sidney Street, Cambridge, Massachusetts 02139 (US). **BARTLE, Laura M.** [GB/US]; 128 Sidney Street, Cambridge, Massachusetts 02139 (US). **SKALETSKAYA, Anna** [US/US]; 128 Sidney Street, Cambridge, Massachusetts 02139 (US). **GOLMAKHER, Viktor S.** [US/US]; 128 Sidney Street, Cambridge, Massachusetts 02139 (US). **TAVARES, Daniel** [US/US]; 128 Sidney Street, Cambridge, Massachusetts 02139 (US). **DECKERT, Jutta** [US/US]; 128 Sidney Street, Cambridge, Massachusetts 02139 (US). **MIKOL, VINCENT** [FR/FR]; c/o Sanofi-Aventis, Département des Brevets, 174 Avenue de France, F-75013 Paris (FR). **BLANC, Véronique** [FR/FR]; c/o Sanofi-aventis, Département des Brevets, 174, Avenue de France, F-75013 Paris (FR).

(74) Agent: **BOUVET, Philippe**; Sanofi-Aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:
26 June 2008

(48) Date of publication of this corrected version:
6 August 2009

(15) Information about Corrections:
see Notice of 6 August 2009

Previous Correction:
see Notice of 5 February 2009

(54) Title: NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER

(57) Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38⁺ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosis, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

WO 2008/047242 A8